SCF ENCYCLOPEDIA ENTRY

LEIGH SYNDROME

SCF MITOCHONDRIAL ENERGY FAILURE & NEUROMETABOLIC SYNCHRONIZATION COLLAPSE DOSSIER

I. OFFICIAL DISEASE CLASSIFICATION

Leigh Syndrome belongs to SCF Clinical Domains C6 (Mitochondrial & Metabolic Biology), C7 (Neurology), C1 (Genomic Medicine), C14 (Developmental Biology), and C2 (Cellular Signaling).

II. CLINICAL DEFINITION

Leigh Syndrome is a severe progressive neurodegenerative disorder caused by defects in mitochondrial energy metabolism.

Characterized by:

• Developmental regression
• Hypotonia
• Brainstem dysfunction
• Movement abnormalities
• Respiratory compromise
• Progressive neurologic deterioration

Primary affected systems:

• Basal ganglia
• Brainstem
• Cerebellum
• Spinal cord
• Peripheral nerves
• Mitochondrial energy systems

Associated conditions:

• Mitochondrial disease
• Developmental regression

III. MAJOR CLASSIFICATIONS

A. mtDNA-Associated Leigh Syndrome

B. Nuclear DNA-Associated Leigh Syndrome

C. SURF1-Associated Leigh Syndrome

D. Pyruvate Dehydrogenase Deficiency–Associated Leigh Syndrome

Associated condition:

• Pyruvate dehydrogenase deficiency

IV. CORE SCF ETIOPATHOGENIC THESIS

Within the Synergistic Compatibility Framework (SCF), Leigh Syndrome represents a systems-level collapse of:

• Cellular energy harmonics
• Neuroenergetic fidelity
• Mitochondrial communication networks
• Developmental bioenergetic synchronization
• Central nervous system resilience

SCF interprets Leigh Syndrome as a decentralized energy-distribution catastrophe in which critical neural infrastructure loses the ATP required to sustain survival, communication, and adaptive function.

V. MITOCHONDRIAL FOUNDATION

Normal Mitochondrial Functions

Mitochondria normally provide:

• ATP generation
• Cellular respiration
• Metabolic regulation
• Calcium homeostasis
• Redox balance
• Apoptotic control

Core Pathophysiologic Mechanisms

VI. MAJOR GENETIC CAUSES

Frequently Involved Genes

Biochemical Targets

Affected systems:

• Complex I
• Complex II
• Complex III
• Complex IV
• Complex V
• Pyruvate metabolism

Associated concept:

• Oxidative phosphorylation

VII. SCF FAULT ARCHITECTURE

VIII. MULTI-OMICS PATHOGENESIS

A. Genomics

Affected pathways:

• Respiratory-chain assembly
• ATP synthesis
• Mitochondrial maintenance
• Cellular respiration

B. Transcriptomics

Dysregulated pathways:

• Energy metabolism
• Oxidative stress responses
• Mitochondrial biogenesis
• Cell-survival signaling

C. Proteomics

Observed abnormalities:

• Respiratory-chain proteins
• ATP synthase components
• Mitochondrial enzymes
• Neuroprotective proteins

D. Metabolomics

Key dysfunction:

• Lactate accumulation
• ATP depletion
• Redox imbalance
• Metabolic bottlenecks

Associated condition:

• Lactic acidosis

E. Neuroenergetics (SCF)

Observed abnormalities:

• Energy-distribution collapse
• Communication instability
• Neural infrastructure failure
• Progressive network degradation

IX. SCF PATHOGENESIS FLOW

Stage 1 — Genetic Defect

Mitochondrial machinery becomes dysfunctional.

Stage 2 — ATP Production Failure

Energy generation declines.

Stage 3 — Metabolic Crisis

Lactate and oxidative stress accumulate.

Stage 4 — Selective Neural Vulnerability

Basal ganglia and brainstem injury emerge.

Stage 5 — Neurodegeneration

Neurologic symptoms progress.

Stage 6 — Multisystem Failure

Advanced disease develops.

X. SYSTEMIC CONSEQUENCES

Associated conditions:

• Hypotonia
• Seizure
• Respiratory failure

XI. RHENOVA INTERPRETATION

Project RHENOVA interprets Leigh Syndrome as a catastrophic neuroenergetic infrastructure collapse syndrome.

RHENOVA Dynamics

• ATP-distribution bottlenecks
• Progressive neural blackouts
• Metabolic overload loops
• Brainstem destabilization
• System-wide energy exhaustion

RHENOVA Biomarkers

Characteristic Imaging Finding

Associated condition:

• Bilateral basal ganglia lesions

XII. DBI INTERPRETATION

The SCF Decentralized Biological Intelligence framework interprets mitochondria as distributed cellular power stations responsible for:

• Energy distribution
• Communication support
• Adaptive responses
• Information processing
• Cellular survival

DBI Failure Features

• Power-grid instability
• Communication interruptions
• Resource shortages
• Progressive infrastructure collapse

This transforms the nervous system from a coordinated information-processing network into an energy-starved system incapable of sustaining biologic operations.

XIII. CLINICAL MANIFESTATIONS

Neurologic Manifestations

• Developmental regression
• Hypotonia
• Ataxia
• Dystonia
• Seizures

Associated conditions:

• Ataxia
• Dystonia

Brainstem Manifestations

• Abnormal eye movements
• Dysphagia
• Respiratory dysfunction

Associated conditions:

• Dysphagia
• Ophthalmoplegia

Metabolic Manifestations

• Lactic acidosis
• Feeding difficulties
• Failure to thrive

Associated condition:

• Failure to thrive

XIV. DIAGNOSTICS

Diagnostic Hallmarks

Energetic principle:

$Mitochondrial\ Dysfunction \Rightarrow ATP\ Depletion$

Neuroenergetic relationship:

$ATP\ Deficiency \Rightarrow Neuronal\ Degeneration$

Clinical consequence:

$Neurodegeneration \Rightarrow Developmental\ Regression\ +\ Respiratory\ Failure$

XV. SCF SYSTEMIC AXIS INVOLVEMENT

XVI. STANDARD OF CARE

Supportive Management

Current treatment is largely supportive.

Examples:

• Thiamine
• Coenzyme Q10

Specialized Therapies

May include:

• Ketogenic dietary approaches in selected cases
• Respiratory support
• Nutritional support
• Physical therapy

Associated therapy:

• Ketogenic diet

XVII. SCF-PCR THERAPEUTIC ARCHITECTURE

A. Preventative (PCR-P)

Goals:

• Early diagnosis
• Avoid metabolic stressors
• Preserve mitochondrial reserve

B. Curative (PCR-C)

Goals:

• Restore oxidative phosphorylation
• Correct genetic defects
• Normalize ATP production

C. Restorative (PCR-R)

Goals:

• Enhance neuroenergetic resilience
• Protect vulnerable neurons
• Improve mitochondrial communication
• Re-establish cellular energy synchronization

XVIII. ETHNOBIOPROSPECTING TARGETS

Note: No botanical therapy can correct the underlying genetic defect. These represent exploratory mitochondrial-support and neuroprotective research domains.

Traditional Chinese Medicine

• Astragalus membranaceus
• Panax ginseng

Ayurveda

• Withania somnifera
• Bacopa monnieri

Vietnamese Thuốc Nam

• Centella asiatica

XIX. SCF API DISCOVERY TARGETS

High-Priority Molecular Targets

• Mitochondrial gene-repair technologies
• Respiratory-chain restoration platforms
• ATP-regeneration therapeutics
• Mitochondrial biogenesis stimulators
• Neuroprotective metabolic therapies
• Brainstem-preservation technologies
• Neuroenergetic synchronization restoration systems

XX. SCF LAYMAN’S SUMMARY

Leigh Syndrome is a severe inherited mitochondrial disease in which cells cannot produce enough energy to support normal brain function. Because the brainstem and basal ganglia require enormous amounts of ATP, they are particularly vulnerable to mitochondrial failure. Children often experience developmental regression, muscle weakness, movement disorders, feeding difficulties, respiratory problems, and progressive neurologic decline. SCF interprets Leigh Syndrome as a catastrophic failure of the body’s cellular power grid, where mitochondrial energy shortages progressively disable the nervous system’s ability to communicate, regulate, and survive.

XXI. STRATEGIC RESEARCH PRIORITIES

1. Mitochondrial gene-repair technologies
2. Respiratory-chain restoration therapies
3. ATP-regeneration platforms
4. Neuroprotective metabolic interventions
5. Mitochondrial biogenesis enhancement systems
6. Brainstem-preservation therapeutics
7. Neuroenergetic synchronization restoration technologies

MASTER REGISTRY INDEX

SCF-LEIGH-0001 — Leigh Syndrome Master Registry

SCF-LEIGH-MITO-0002 — Mitochondrial Energy Failure Layer

SCF-LEIGH-NEURO-0003 — Neurodegeneration Layer

SCF-LEIGH-RHENOVA-0004 — Neuroenergetic Infrastructure Collapse Layer

SCF-LEIGH-DBI-0005 — Cellular Power-Grid Failure Layer

SCF-LEIGH-PCR-0006 — Preventative–Curative–Restorative Layer